| DIRECT COMPETITOR COMPARISON | |
| URGP.OB | Pvt1 | Pvt2 | Pvt3 | Industry | | Market Cap: | 7.74M | N/A | N/A | N/A | 104.17M | | Employees: | 2 | N/A | N/A | N/A | 63 | | Qtrly Rev Growth (yoy): | N/A | N/A | N/A | N/A | 19.10% | | Revenue (ttm): | N/A | 9.93B1 | 15.81B1 | N/A | 13.84M | | Gross Margin (ttm): | N/A | N/A | N/A | N/A | 65.67% | | EBITDA (ttm): | -1.61M | N/A | N/A | N/A | -11.86M | | Oper Margins (ttm): | N/A | N/A | N/A | N/A | -149.46% | | Net Income (ttm): | -2.04M | 1.76B1 | 2.41B1 | N/A | N/A | | EPS (ttm): | -0.028 | N/A | N/A | N/A | -0.31 | | P/E (ttm): | N/A | N/A | N/A | N/A | 17.44 | | PEG (5 yr expected): | N/A | N/A | N/A | N/A | 1.35 | | P/S (ttm): | N/A | N/A | N/A | N/A | 10.43 |
|
| BIOTECHNOLOGY COMPANIES RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Amgen Inc. | AMGN | 57.54 | 0.03% | 58.24B | 12.55 | | Genentech, Inc. | Private - View Profile | | Biogen Idec Inc. | BIIB | 53.70 | 0.56% | 15.53B | 17.97 | | Genzyme Corp. | GENZ | 49.75 | -0.12% | 13.20B | 28.36 | | Merck Serono S.A. | Private - View Profile | | Chiron Corporation | Private - View Profile | | Gilead Sciences Inc. | GILD | 43.80 | 0.76% | 39.42B | 16.94 | | MedImmune, Inc. | Private - View Profile | | Life Technologies Corporation | LIFE | 52.43 | -0.11% | 9.35B | 1070.00 | | Teva Pharmaceutical Industries Limited | TEVA | 55.88 | 0.68% | 49.23B | 51.13 |
|
| GENERIC DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | Sandoz International GmbH | Private - View Profile | | Watson Pharmaceuticals Inc. | WPI | 39.82 | -0.20% | 4.23B | 20.53 | | King Pharmaceuticals Inc. | KG | 12.31 | 0.00% | 3.06B | N/A | | Ranbaxy Laboratories Limited | Private - View Profile | | Mylan, Inc. | MYL | 18.61 | 0.00% | 5.69B | 114.17 | | Pfizer Inc. | PFE | 18.50 | -0.32% | 149.29B | 15.37 | | Johnson & Johnson | JNJ | 64.91 | -0.05% | 179.09B | 14.18 | | GlaxoSmithKline plc | GSK | 42.50 | 0.12% | 107.74B | 13.89 | | Sanofi-Aventis | SNY | 39.77 | -1.34% | 103.84B | N/A | | Novartis AG | NVS | 54.64 | -0.42% | 124.10B | 16.36 |
|
| DRUGMAKERS RANKED BY SALES | |
|
| Company | Symbol | Price | Change | Market Cap | P/E | | RHHBY.PK | 42.30 | -1.86% | N/A | N/A | | AstraZeneca plc | AZN | 47.00 | 0.82% | 68.15B | 9.44 | | Abbott Laboratories | ABT | 54.54 | 0.52% | 84.36B | 14.78 | | Bristol-Myers Squibb Co. | BMY | 25.61 | 0.31% | 50.73B | 13.25 |
|
| NEWS ON DIRECT COMPETITORS | | No News on Direct Competitors |
|
|